x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012853
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human |
| Applications | WB, IP, IF |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gly366 of human sphingosine-1-phosphate receptor 1 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | S1PR1 |
| UniProt No. | P21453 |
| Gene ID | 1901 |
| Gene Description | Sphingosine-1-phosphate receptor 1 is a G protein-coupled receptor, one of five members belonging to the sphingosine-1-phosphate receptor family. This family of GPCRs has been shown to exhibit broad and often overlapping expression patterns across a wide array of tissues. The cognate ligand for S1PRs is sphingosine-1-phosphate, a phosphorylated lipid signaling molecule derived from sphingosine. S1P/S1PR binding can trigger the activation and/or inhibition of various downstream signaling pathways, depending on context. Pathways identified downstream of S1P/S1PR include PI3K/Akt, PLC, Ras/MAPK and PKA. S1P/S1PR1 signaling pathways play important roles in many basic cellular functions during normal development, including chemotaxis, vascular integrity, and immune cell egress, but can also contribute to a variety of pathological conditions, including atherogenesis, multiple sclerosis, and tumorigenesis. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
